NCT06760390

Brief Summary

This study aims to evaluate the autonomic differences in heart rate variability (HRV) between healthy individuals and those with chronic low back pain. By analyzing HRV parameters, such as time-domain, frequency-domain, and non-linear metrics, this cross-sectional study seeks to explore the impact of chronic pain on the autonomic nervous system. The study will provide insights into parasympathetic and sympathetic modulation and its potential relationship with chronic pain symptoms. Participants include healthy adults and individuals with chronic low back pain aged 18-65.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
98

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2020

Completed
29 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2020

Completed
4.1 years until next milestone

First Submitted

Initial submission to the registry

December 29, 2024

Completed
8 days until next milestone

First Posted

Study publicly available on registry

January 6, 2025

Completed
Last Updated

January 6, 2025

Status Verified

December 1, 2024

Enrollment Period

29 days

First QC Date

December 29, 2024

Last Update Submit

December 29, 2024

Conditions

Outcome Measures

Primary Outcomes (5)

  • Root Mean Square of Successive Differences (rMSSD)

    This variable represents a time-domain measure of heart rate variability, reflecting parasympathetic nervous system activity and short-term variability in R-R intervals. It is calculated as the root mean square of differences between successive R-R intervals. rMSSD is an established metric to assess vagal modulation and is sensitive to changes in autonomic function.

    Measured during a single 30-minute session, including a 5-minute baseline and 25-minute data collection period.

  • SD1 (Short-Term Variability)

    A non-linear metric derived from the Poincaré plot of heart rate variability, indicating short-term variability in R-R intervals. It is closely associated with parasympathetic activity and vagal modulation.

    Measured during a single 30-minute session, including a 5-minute baseline and 25-minute data collection period.

  • SD2 (Long-Term Variability)

    A non-linear metric derived from the Poincaré plot, representing long-term variability in R-R intervals. SD2 is inversely related to sympathetic activity and reflects the balance between sympathetic and parasympathetic modulation.

    Measured during a single 30-minute session, including a 5-minute baseline and 25-minute data collection period.

  • Stress Score (SS)

    This variable is calculated as the reciprocal of SD2, multiplied by 1000. It reflects the level of sympathetic activation, where higher Stress Score values indicate increased stress and reduced parasympathetic activity.

    Measured during a single 30-minute session, including a 5-minute baseline and 25-minute data collection period.

  • Sympathetic/Parasympathetic Ratio (S/PS Ratio)

    This variable represents the ratio of Stress Score to SD1. It reflects the balance between sympathetic and parasympathetic modulation, with higher values indicating sympathetic dominance, commonly observed in chronic pain conditions.

    Measured during a single 30-minute session, including a 5-minute baseline and 25-minute data collection period.

Secondary Outcomes (3)

  • Mean Heart Rate (Mean HR)

    Measured during a single 30-minute session, including a 5-minute baseline and 25-minute data collection period.

  • Minimum Heart Rate (Min HR)

    Measured during a single 30-minute session, including a 5-minute baseline and 25-minute data collection period.

  • Maximum Heart Rate (Max HR)

    Measured during a single 30-minute session, including a 5-minute baseline and 25-minute data collection period.

Study Arms (2)

Healthy Subjects

This group includes adults aged 18-65 years without any chronic or acute pathology, no regular medication that could alter autonomic nervous system function, and no low back pain in the past six months.

Chronic Low Back Pain Subjects

This group includes adults aged 18-65 years diagnosed with chronic low back pain lasting at least three months, with a minimum pain intensity of 3/10 on the Numerical Pain Rating Scale, and without uncontrolled neurological or cardiac disorders.

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The study includes two groups: one group of adults diagnosed with chronic low back pain, aged 18-65 years, and another group of healthy adults within the same age range. Participants were recruited from local community advertisements and hospital outpatient clinics.

You may qualify if:

  • Adults aged between 18 and 65 years.
  • For the chronic low back pain group:
  • Diagnosis of chronic low back pain lasting at least three months.
  • A minimum pain intensity of 3/10 on the Numerical Pain Rating Scale (NPRS).
  • For the healthy group:
  • Absence of any chronic or acute pathology.
  • No regular medication that could alter autonomic nervous system function.
  • No episodes of low back pain in the past six months.

You may not qualify if:

  • Presence of uncontrolled neurological or cardiac disorders.
  • Use of medications that could influence autonomic function or pain perception (e.g., opioids, antidepressants, benzodiazepines, anti-inflammatory drugs, beta-blockers) within two weeks prior to the study.
  • Body Mass Index (BMI) equal to or greater than 30 kg/m².

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Universidad de Extremadura

Badajoz, Badajoz, 06006, Spain

Location

Study Officials

  • Luis Espejo-Antúnez, Ph.D.

    University of Extremadura

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Professor

Study Record Dates

First Submitted

December 29, 2024

First Posted

January 6, 2025

Study Start

November 1, 2020

Primary Completion

November 30, 2020

Study Completion

November 30, 2020

Last Updated

January 6, 2025

Record last verified: 2024-12

Locations